Read + Share
Amedeo Smart
Independent Medical Education
Vora SM, Boyd S, Denny N, Jackson E, et al. Expanded eligibility for emerging therapies in sickle cell disease in the UK - crizanlizumab and voxelotor. Br J Haematol 2022;197:502-504.PMID: 35189668
Email
LinkedIn
Facebook
Twitter
Privacy Policy